Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome
Status:
Completed
Trial end date:
2020-07-29
Target enrollment:
Participant gender:
Summary
This is a pilot study examining the efficacy, safety and tolerability of intranasal oxytocin
as a novel treatment in Phelan-McDermid syndrome (PMS). This study will utilize a randomized,
placebo-controlled design for 12 weeks (phase 1), followed by an open-label extension for 12
weeks (phase 2). The purpose is to evaluate the effect of intranasal oxytocin on impairments
in attention, social memory, socialization, language, and repetitive behaviors.